TY - JOUR
T1 - Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis
AU - Zhang, Kathleen W.
AU - Stockerl-Goldstein, Keith E.
AU - Lenihan, Daniel J.
N1 - Publisher Copyright:
© 2019 The Authors
PY - 2019/6
Y1 - 2019/6
N2 - Cardiac amyloidosis is a restrictive cardiomyopathy that results from the deposition of misfolded light chain or transthyretin proteins, most commonly, in cardiac tissue. Traditionally, treatment options for light chain (AL) and transthyretin (ATTR) amyloidosis have been limited. However, there are now multiple novel therapeutics in development and several therapeutics recently approved that promise to revolutionize clinical management of AL and ATTR. Most of these agents disrupt specific stages of amyloidogenesis such as light chain or transthyretin protein production, formation of amyloidogenic intermediates, or amyloid fibril aggregation. Others aim to remove existing amyloid tissue deposits using monoclonal antibody technology. Although these advances represent an important step forward in the care of cardiac amyloidosis patients, additional studies are needed to define the optimal treatment paradigms for AL and ATTR and to validate clinical, imaging, or serum biomarker strategies that may confirm a cardiac response to therapy.
AB - Cardiac amyloidosis is a restrictive cardiomyopathy that results from the deposition of misfolded light chain or transthyretin proteins, most commonly, in cardiac tissue. Traditionally, treatment options for light chain (AL) and transthyretin (ATTR) amyloidosis have been limited. However, there are now multiple novel therapeutics in development and several therapeutics recently approved that promise to revolutionize clinical management of AL and ATTR. Most of these agents disrupt specific stages of amyloidogenesis such as light chain or transthyretin protein production, formation of amyloidogenic intermediates, or amyloid fibril aggregation. Others aim to remove existing amyloid tissue deposits using monoclonal antibody technology. Although these advances represent an important step forward in the care of cardiac amyloidosis patients, additional studies are needed to define the optimal treatment paradigms for AL and ATTR and to validate clinical, imaging, or serum biomarker strategies that may confirm a cardiac response to therapy.
KW - cardiac amyloidosis
KW - clinical trials
KW - therapeutics
UR - http://www.scopus.com/inward/record.url?scp=85067261202&partnerID=8YFLogxK
U2 - 10.1016/j.jacbts.2019.02.002
DO - 10.1016/j.jacbts.2019.02.002
M3 - Review article
C2 - 31312767
AN - SCOPUS:85067261202
SN - 2452-302X
VL - 4
SP - 438
EP - 448
JO - JACC: Basic to Translational Science
JF - JACC: Basic to Translational Science
IS - 3
ER -